source
- FDA Grants First Gene-Therapy Approval for Children 2+ with Sickle Cell DiseaseThe U.S. Food and Drug Administration issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged two years and older who have sickle cell disease with recurrent vaso-oc…
- Ipsen to acquire Swiss biotech Memo Therapeutics in up to €800 million deal for BK virus drugIpsen announced it will purchase Memo Therapeutics, a Swiss biotech, in a transaction valued at up to about €800 million. The agreement provides Memo investors with €200 million upfront and potent…